Melodia Therapeutics is advancing a next-generation DPP1 inhibitor to transform the treatment of severe neutrophil-driven inflammatory diseases.

Location

Additional address info

  • c/o Walder Wyss AG

Canton

Facts & figures

  • Type of organization
    Private company
  • Year of foundation
    2024
  • Number of employees in Switzerland
    1-9

Key business

Keep browsing

You may also be interested in